-
公开(公告)号:US08450350B2
公开(公告)日:2013-05-28
申请号:US13101970
申请日:2011-05-05
申请人: Adilah Bahadoor , Alfredo C. Castro , Lawrence K. Chan , Gregg F. Keaney , Marta Nevalainen , Vesa Nevalainen , Stephane Peluso , Thomas T. Tibbitts
发明人: Adilah Bahadoor , Alfredo C. Castro , Lawrence K. Chan , Gregg F. Keaney , Marta Nevalainen , Vesa Nevalainen , Stephane Peluso , Thomas T. Tibbitts
IPC分类号: A61K31/41 , A61K31/4192 , C07D249/00 , C07D249/06
CPC分类号: A61K31/4192 , A61K31/454 , A61K31/4709 , A61K45/06 , C07D249/04 , C07D249/06 , C07D249/18 , C07D401/06 , C07D401/12 , C07D471/04
摘要: Provided herein are triazole FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, X, RB, and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
摘要翻译: 本文提供式(I)的三唑FASN抑制剂:或其药学上可接受的形式; 其中变量RA,X,RB和RC在本文中定义。 本文还提供本文提供的化合物的药物组合物及其用于治疗各种疾病如过度增殖性疾病,炎症性疾病,肥胖相关病症和微生物感染的方法。
-
公开(公告)号:US08546432B2
公开(公告)日:2013-10-01
申请号:US13101978
申请日:2011-05-05
申请人: Adilah Bahadoor , Alfredo C. Castro , Lawrence K. Chan , Gregg F. Keaney , Marta Nevalainen , Vesa Nevalainen , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Adilah Bahadoor , Alfredo C. Castro , Lawrence K. Chan , Gregg F. Keaney , Marta Nevalainen , Vesa Nevalainen , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: A61K31/41 , C07D249/00
CPC分类号: A61K31/41 , A61K31/4184 , A61K31/428 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/497 , A61K31/5377 , A61K31/5415 , A61K31/55 , A61K31/7056 , A61K38/21 , A61K38/212 , A61K38/217 , A61K45/06 , C07D257/04 , C07D295/185 , C07D295/205 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/12 , C07D407/12 , C07D413/06 , C07D413/12 , C07D417/04 , C07D417/06 , Y02A50/385 , Y02A50/387 , Y02A50/393 , Y02A50/397 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/421 , Y02A50/422 , Y02A50/423 , Y02A50/478 , Y02A50/491 , Y02A50/492
摘要: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
摘要翻译: 本文提供式(I)的四唑酮FASN抑制剂:或其药学上可接受的形式; 其中变量RA,RB和RC在本文中定义。 本文还提供本文提供的化合物的药物组合物及其用于治疗各种疾病如过度增殖性疾病,炎症性疾病,肥胖相关病症和微生物感染的方法。
-
公开(公告)号:US20110274655A1
公开(公告)日:2011-11-10
申请号:US13101978
申请日:2011-05-05
申请人: Adilah BAHADOOR , Alfredo C. Castro , Lawrence K. Chan , Gregg F. Keaney , Marta Nevalainen , Vesa Nevalainen , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Adilah BAHADOOR , Alfredo C. Castro , Lawrence K. Chan , Gregg F. Keaney , Marta Nevalainen , Vesa Nevalainen , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: A61K31/41 , C07D417/10 , C07D403/10 , C07D401/06 , C07D401/12 , C07D413/12 , C07D417/06 , A61K31/433 , A61K31/454 , A61K31/4439 , A61K31/496 , A61K31/5377 , A61K31/5415 , A61K31/55 , A61K38/21 , A61K31/7056 , A61P33/02 , A61P33/06 , A61P33/00 , A61P31/10 , A61P31/04 , A61P31/12 , A61P31/16 , A61P29/00 , A61P3/04 , A61P3/10 , A61P1/16 , C07D257/04
CPC分类号: A61K31/41 , A61K31/4184 , A61K31/428 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/497 , A61K31/5377 , A61K31/5415 , A61K31/55 , A61K31/7056 , A61K38/21 , A61K38/212 , A61K38/217 , A61K45/06 , C07D257/04 , C07D295/185 , C07D295/205 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/12 , C07D407/12 , C07D413/06 , C07D413/12 , C07D417/04 , C07D417/06 , Y02A50/385 , Y02A50/387 , Y02A50/393 , Y02A50/397 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/421 , Y02A50/422 , Y02A50/423 , Y02A50/478 , Y02A50/491 , Y02A50/492
摘要: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein.Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
摘要翻译: 本文提供式(I)的四唑酮FASN抑制剂:或其药学上可接受的形式; 其中变量RA,RB和RC在本文中定义。 本文还提供本文提供的化合物的药物组合物及其用于治疗各种疾病如过度增殖性疾病,炎症性疾病,肥胖相关病症和微生物感染的方法。
-
公开(公告)号:US20110274654A1
公开(公告)日:2011-11-10
申请号:US13101970
申请日:2011-05-05
申请人: Adilah BAHADOOR , Alfredo C. Castro , Lawrence K. Chan , Gregg F. Keaney , Marta Nevalainen , Vesa Nevalainen , Stephane Peluso , Thomas T. Tibbitts
发明人: Adilah BAHADOOR , Alfredo C. Castro , Lawrence K. Chan , Gregg F. Keaney , Marta Nevalainen , Vesa Nevalainen , Stephane Peluso , Thomas T. Tibbitts
IPC分类号: A61K38/21 , C07D249/04 , A61K31/4709 , A61K31/454 , A61K31/4192 , A61K31/7056 , A61P31/04 , A61P31/10 , A61P31/06 , A61P33/00 , A61P33/02 , A61P33/12 , A61P33/10 , A61P33/04 , A61P33/06 , C07D401/06
CPC分类号: A61K31/4192 , A61K31/454 , A61K31/4709 , A61K45/06 , C07D249/04 , C07D249/06 , C07D249/18 , C07D401/06 , C07D401/12 , C07D471/04
摘要: Provided herein are triazole FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, X, RB, and RC are defined herein.Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
摘要翻译: 本文提供式(I)的三唑FASN抑制剂:或其药学上可接受的形式; 其中变量RA,X,RB和RC在本文中定义。 本文还提供本文提供的化合物的药物组合物及其用于治疗各种疾病如过度增殖性疾病,炎症性疾病,肥胖相关病症和微生物感染的方法。
-
公开(公告)号:US09149465B2
公开(公告)日:2015-10-06
申请号:US12782650
申请日:2010-05-18
申请人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: C07D261/04 , A61K31/5377 , A61K31/42 , A61K31/4245 , A61K31/4439 , A61K31/4709 , A61K31/501 , A61K31/506 , C07D413/04 , C07D413/12 , C07D413/14 , C07D471/04
CPC分类号: A61K31/42 , A61K31/4245 , A61K31/4439 , A61K31/4709 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D261/04 , C07D413/04 , C07D413/12 , C07D413/14 , C07D471/04
摘要: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
摘要翻译: 本发明提供式(I)的异恶唑啉FAAH抑制剂或其药学上可接受的形式,其中G,Ra,Rb,Rc和Rd各自如本文所定义。 本发明还提供包含式(I)化合物或其药学上可接受的形式的药物组合物和药学上可接受的赋形剂。 本发明还提供了治疗FAAH介导的病症的方法,包括向有需要的受试者施用治疗有效量的式(I)化合物或其药学上可接受的形式。
-
公开(公告)号:US08765735B2
公开(公告)日:2014-07-01
申请号:US12782658
申请日:2010-05-18
申请人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: A01N43/00 , A61K31/55 , A01N43/42 , A61K31/44 , A01N43/80 , A61K31/42 , C07D261/02 , C07D401/00
CPC分类号: C07D498/10 , A61K31/42 , A61K31/438 , A61K31/55 , C07D261/20 , C07D498/04
摘要: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
摘要翻译: 本发明提供式(I)的异恶唑啉FAAH抑制剂或其药学上可接受的形式,其中G,Ra,Rb,Rc和Rd各自如本文所定义。 本发明还提供包含式(I)化合物或其药学上可接受的形式的药物组合物和药学上可接受的赋形剂。 本发明还提供了治疗FAAH介导的病症的方法,包括向有需要的受试者施用治疗有效量的式(I)化合物或其药学上可接受的形式。
-
公开(公告)号:US20110028478A1
公开(公告)日:2011-02-03
申请号:US12782650
申请日:2010-05-18
申请人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: A61K31/5377 , C07D261/04 , A61K31/42 , A61P29/00 , A61P27/06 , A61P9/10 , A61P37/00 , A61P17/00 , A61P25/28 , A61P1/08 , A61P25/30 , A61P9/12 , A61P3/04 , C07D413/12 , A61K31/4439 , A61K31/506 , A61K31/501 , C07D413/10 , A61K31/4245 , A61K31/4709
CPC分类号: A61K31/42 , A61K31/4245 , A61K31/4439 , A61K31/4709 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D261/04 , C07D413/04 , C07D413/12 , C07D413/14 , C07D471/04
摘要: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
-
公开(公告)号:US08927551B2
公开(公告)日:2015-01-06
申请号:US12782655
申请日:2010-05-18
申请人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: A61K31/498 , C07D413/04 , A61K31/4439 , C07D401/14 , A61K31/506 , A61K31/424 , C07D401/04 , A61K31/454 , C07D413/06 , A61K31/496 , C07D403/10 , C07D401/10 , C07D417/04 , C07D417/14 , C07D413/14 , C07D261/04
CPC分类号: C07D413/04 , C07D261/04 , C07D413/14 , C07D417/04 , C07D417/14
摘要: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
-
9.
公开(公告)号:US20110028482A1
公开(公告)日:2011-02-03
申请号:US12782655
申请日:2010-05-18
申请人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: A61K31/498 , C07D413/04 , A61K31/42 , C07D417/14 , A61K31/4439 , C07D401/14 , A61K31/506 , A61K31/427 , C07D401/04 , A61K31/454 , C07D413/06 , A61K31/496 , C07D417/10 , A61K31/428 , C07D403/10 , C07D401/10 , A61K31/4709 , A61P1/00 , A61P3/00 , A61P9/00 , A61P17/00 , A61P25/00 , A61P27/06 , A61P29/00
CPC分类号: C07D413/04 , C07D261/04 , C07D413/14 , C07D417/04 , C07D417/14
摘要: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
摘要翻译: 本发明提供式(I)的异恶唑啉FAAH抑制剂或其药学上可接受的形式,其中G,Ra,Rb,Rc和Rd各自如本文所定义。 本发明还提供包含式(I)化合物或其药学上可接受的形式的药物组合物和药学上可接受的赋形剂。 本发明还提供了治疗FAAH介导的病症的方法,包括向有需要的受试者施用治疗有效量的式(I)化合物或其药学上可接受的形式。
-
公开(公告)号:US20110034437A1
公开(公告)日:2011-02-10
申请号:US12782658
申请日:2010-05-18
申请人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: A61K31/55 , C07D261/20 , A61K31/42 , A61K31/438 , C07D498/10 , A61P25/00 , A61P3/00 , A61P9/00 , A61P1/08 , A61P25/28 , A61P25/30 , A61P25/20 , A61P3/04
CPC分类号: C07D498/10 , A61K31/42 , A61K31/438 , A61K31/55 , C07D261/20 , C07D498/04
摘要: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
-
-
-
-
-
-
-
-
-